Arcus Biosciences (NYSE:RCUS) Hits New 1-Year High – Should You Buy?

Arcus Biosciences, Inc. (NYSE:RCUS)’s share price reached a new 52-week high during trading on Thursday . The stock traded as high as $28.72 and last traded at $26.6850, with a volume of 4111890 shares trading hands. The stock had previously closed at $24.52.

More Arcus Biosciences News

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Short?term rebound: RCUS shares moved higher intraday as investors bought the dip following yesterday’s selloff; market reports highlight increased trading activity today. Read More.
• Positive Sentiment: Volume and price surge: Analysts and market commentary noted a roughly single?digit percentage uptick with above?average volume, suggesting short?covering and speculative flows helped lift the stock. Read More.
• Neutral Sentiment: Upcoming investor event: Management will host a conference call on May 5 to discuss Q1 2026 results and pipeline updates — this scheduled update creates a near?term catalyst that could clarify program decisions. Read More.
• Neutral Sentiment: Analyst caution: Commentary warns the recent rebound may not be durable — earnings?estimate revisions and fundamental recovery depend on pipeline readouts and partner decisions. Read More.
• Negative Sentiment: Partner pullback on TIGIT programs: Reports say Gilead has scaled back its TIGIT effort after late?stage failures, prompting culls of multiple TIGIT trials that involve partners including Arcus — a major negative for Arcus’ TIGIT?linked pipeline strategy and collaboration value. Read More.
• Negative Sentiment: Discontinued lung?cancer trial with Gilead: Arcus announced halting a lung cancer study tied to the TIGIT program, which triggered earlier selling and raises questions about near?term clinical progress and partner support. Read More.

Analysts Set New Price Targets

RCUS has been the subject of several research reports. Wedbush increased their target price on Arcus Biosciences from $37.00 to $41.00 and gave the company an “outperform” rating in a research report on Thursday, April 2nd. Truist Financial upgraded Arcus Biosciences to a “strong-buy” rating in a research report on Wednesday, March 25th. Wall Street Zen upgraded Arcus Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Leerink Partners set a $47.00 price objective on Arcus Biosciences in a research report on Monday. Finally, Morgan Stanley restated an “equal weight” rating and set a $20.00 price objective (down from $23.00) on shares of Arcus Biosciences in a research report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Arcus Biosciences has a consensus rating of “Moderate Buy” and an average target price of $32.44.

Arcus Biosciences Stock Up 8.8%

The company has a debt-to-equity ratio of 0.16, a current ratio of 4.36 and a quick ratio of 4.36. The company has a market capitalization of $3.34 billion, a P/E ratio of -8.09 and a beta of 0.86. The stock has a 50-day moving average price of $21.87 and a 200-day moving average price of $21.45.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.22. Arcus Biosciences had a negative return on equity of 65.77% and a negative net margin of 142.91%.The company had revenue of $33.00 million during the quarter, compared to the consensus estimate of $24.94 million. During the same period last year, the company earned ($1.03) earnings per share. The firm’s revenue was down 8.3% compared to the same quarter last year. On average, research analysts predict that Arcus Biosciences, Inc. will post -3.72 EPS for the current fiscal year.

Institutional Investors Weigh In On Arcus Biosciences

A number of hedge funds have recently added to or reduced their stakes in RCUS. AQR Capital Management LLC increased its holdings in Arcus Biosciences by 253.9% in the first quarter. AQR Capital Management LLC now owns 90,954 shares of the company’s stock worth $714,000 after purchasing an additional 65,254 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Arcus Biosciences by 10.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,572 shares of the company’s stock worth $297,000 after purchasing an additional 3,565 shares in the last quarter. Millennium Management LLC increased its holdings in Arcus Biosciences by 29.2% in the first quarter. Millennium Management LLC now owns 1,194,622 shares of the company’s stock worth $9,378,000 after purchasing an additional 270,253 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Arcus Biosciences by 106.2% in the first quarter. Goldman Sachs Group Inc. now owns 914,208 shares of the company’s stock worth $7,177,000 after purchasing an additional 470,755 shares in the last quarter. Finally, Strs Ohio bought a new stake in Arcus Biosciences in the first quarter worth approximately $67,000. 92.89% of the stock is currently owned by institutional investors.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.